Related Experiment Video
Updated: Sep 5, 2025

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
Published on: September 28, 2015
AT2 Receptor Stimulation Inhibits Vascular Smooth Muscle Cell Senescence Induced by Angiotensin II and Hyperglycemia
Hui-Yu Bai1, Hui Li1, Xiang Zhou1
1Department of Cardiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Background:
Hyperglycemia has been widely reported to induce vascular senescence. We have previously demonstrated that angiotensin II (Ang II) could promote brain vascular smooth muscle cell (VSMC) senescence, and its type 2 (AT2) receptor deletion could enhance VSMC senescence. Therefore, we examined the possible cross-talk between Ang II and hyperglycemia on VSMC senescence, and the roles of AT2 receptor agonist, compound 21 (C21) on it.
Methods:
Aortic VSMCs were prepared from adult male mice and stimulated with Ang II and/or high glucose (Glu) and/or C21 and/or an autophagy inhibitor, 3-methyladenine (3-MA), and/or an autophagy agonist, rapamycin (RAP) for the indicated times. Cellular senescence, oxidative stress, and protein expressions were evaluated.
Results:
Combination treatment with Ang II and Glu synergistically increased the proportion of VSMC senescent area compared with control group and each treatment alone, which was almost completely attenuated by C21 treatment. Moreover, combination treatment induced significant changes in the levels of superoxide anion, the expressions of p21 and pRb, and the ratio of LC3B II/I expression, which were also significantly attenuated by C21 treatment. The proportion of VSMC senescent area and the levels of superoxide anion by combination treatment were increased after 3-MA treatment, and the proportion of senescent area and the expressions of p21 and pRb were decreased after RAP treatment, both of which were further attenuated by C21 treatment.
Conclusions:
Ang II and hyperglycemia synergistically promoted VSMC senescence, at least partly through the participation by autophagy, oxidative stress, and p21-pRb pathway, which could be inhibited by C21.
Insights
High glucose and angiotensin II (Ang II) accelerate vascular smooth muscle cell (VSMC) senescence. The AT2 receptor agonist C21 effectively inhibits this synergistic effect, highlighting its therapeutic potential.
Area of Science:
- Vascular Biology
- Cellular Senescence
- Endocrinology
Background:
- Hyperglycemia is a known inducer of vascular senescence.
- Angiotensin II (Ang II) promotes vascular smooth muscle cell (VSMC) senescence, with AT2 receptor deletion enhancing this effect.
- The interplay between Ang II and hyperglycemia in VSMC senescence requires further investigation.
Purpose of the Study:
- To investigate the synergistic effects of Ang II and hyperglycemia on VSMC senescence.
- To determine the role of the AT2 receptor agonist, compound 21 (C21), in modulating Ang II and hyperglycemia-induced VSMC senescence.
Main Methods:
- Aortic VSMCs were isolated from male mice.
- Cells were treated with Ang II, high glucose (Glu), C21, and modulators of autophagy (3-MA, rapamycin).
- Evaluated senescence, oxidative stress (superoxide anion), and protein expression (p21, pRb, LC3B II/I).
Main Results:
- Combined Ang II and Glu synergistically increased VSMC senescence and oxidative stress.
- C21 treatment significantly attenuated the senescence and oxidative stress induced by combined Ang II and Glu.
- Autophagy modulation influenced senescence, with C21 providing further inhibition.
Conclusions:
- Ang II and hyperglycemia synergistically promote VSMC senescence.
- This process involves autophagy, oxidative stress, and the p21-pRb pathway.
- C21 demonstrates inhibitory effects on Ang II and hyperglycemia-induced VSMC senescence.
More Related Videos
12:03Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
08:41Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues
Published on: June 3, 2019
Related Concept Videos
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hypertension II: Pathophysiology
Antihypertensive Drugs: Action of β1 Blockers